An observational study in Mucopolysaccharidosis Type IIIB, Mucopolysaccharidosis Type 3 B and MPS III B, sponsored by Allievex Corporation. Completed at 8 sites in 8 countries. Open to participants aged 1 Year to 10 Years. Per ClinicalTrials.gov, last updated 2020-03-06.
Sponsored by Allievex Corporation · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies in Mucopolysaccharidosis III with a site in United States — 12 open to participants now, 15 under way, 4 of them phase 3. Mucopolysaccharidosis III · United States.
Among the 43 studies in Mucopolysaccharidosis III with a site in United States, this one is the 13th largest by enrollment of the 19 observational ones that give a count, is one of 3 that started in 2015, is one of 19 observational ones, and was the 16th registered.
58 studies on the registry are indexed under Mucopolysaccharidosis III; 16 are open to participants now.
Browse Mucopolysaccharidosis III studies →12 of the 43 studies in Mucopolysaccharidosis III with a site in United States are open now. Recruiting first, the newest first:
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center · Sites in United States
Ages 4+
Ozlem Goker-Alpan · Sites in United States
Ages 18–99
Phoenix Nest · Sites in United States, France
Ages 12 mo+
Denali Therapeutics Inc. · Sites in United States
Ages 0–18
Lysosomal and Rare Disorders Research and Treatment Center, Inc. · Sites in United States
Ages 5–99
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 8 Mucopolysaccharidosis III studies recruiting now, 5 set no upper age limit and 1 stops at 75 or younger; 7 take children under 18; none take healthy volunteers.
This study: 1 Year to 10 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 18 · Phase 3 6 · Phase 4 1
First in 2006; this study’s year is marked. 3 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 22 is below the median of 30 across 24 observational studies indexed under Mucopolysaccharidosis III.
Median enrollment 17 across the 23 interventional studies, 30 across the 19 observational. Of the 25 that completed or were terminated, 10 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
30 of 43 have an industry lead sponsor. The 10 most frequent:
Allievex Corporation is the lead sponsor of 5 studies on the registry; 1 is open to participants now.
Allievex Corporation has 5 studies filed under Mucopolysaccharidosis III — fewer than ten, so there is no comparison to draw.
5 of the studies in Mucopolysaccharidosis III with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06333041Phase 3Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical CenterStudy of Cannabidiol in Sanfilippo Syndrome | 2027-04 |
| NCT04360265Phase 3Ultragenyx Pharmaceutical IncFollow-up Study of AAV-Mediated Gene Transfer (UX111; Previously Known as ABO-102) for MPS Type IIIA | 2027-08 |
| NCT03655223RTI InternationalEarly Check: Expanded Screening in Newborns | 2026-11-30 |
| NCT06567769GC Biopharma CorpPhase 1 Study of GC1130A in Patients With Sanfilippo Syndrome Type A (MPS IIIA) | 2027-06 |
| NCT05492799Allievex CorporationSafety, Tolerability and Efficacy of ICV AX 250 Treatment in MPS IIIB -OLE | 2027-10 |
Add all 5 to your calendar (.ics) → With an account.
Among the 43 studies in Mucopolysaccharidosis III with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Mucopolysaccharidosis type IIIB (MPS IIIB, also known as Sanfilippo Syndrome Type B) is a severe neurodegenerative disorder. The purpose of this study is to learn more about the health problems in patients with MPS IIIB and how to measure these problems over time. It will particularly look at how the disease develops in young children. This is an observational study, so no experimental drug will be given. The results from this study will help us design future studies to measure whether these health problems get better when we give experimental drug for MPS IIIB.
This is a multicenter, multinational, longitudinal, observational study in subjects 1 through 10 years of age who have been diagnosed with MPS IIIB. Data will be prospectively collected from 20 to 30 subjects to understand the clinical progression of MPS IIIB in terms of neurocognitive function, behavior, quality of life, imaging characteristics, genotype, and biochemical markers of disease burden. This information may help inform the design and interpretation of subsequent interventional studies.
Study Population: Subjects diagnosed with MPS IIIB
Males and females 1 through 10 years of age (ie, until they turn 11) with a documented diagnosis of MPS IIIB are eligible to participate in this observational study. Up to approximately 5 subjects 6 to 10 years old, inclusive, will be enrolled; the remaining subjects will be 1 to 5 years old, inclusive. Additional entry criteria follow.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Neurocognitive function
A neurodevelopmental assessment will be performed using standardized developmental tests to provide quantifiable measures of neurocognitive function.
Time frame: Screening, baseline, and every 12 weeks, for up to 48-96 weeks
Imaging characteristics
MRI will be used to assess changes in size of various organs affected by the disease, including brain, liver and spleen.
Time frame: Baseline and every 24 weeks, for up to 48-96 weeks
Behavioral function
Disease-related behaviors will be assessed using an MPS III-specific behavior rating scale.
Time frame: Baseline and every 12 weeks, for up to 48-96 weeks
Hearing
The function of conductive and sensorineural hearing pathways will be assessed using tympanometry and auditory brainstem response (ABR).
Time frame: Baseline and every 24 weeks, for up to 48-96 weeks
Sleep habits
Patient sleep habits will be assessed using specific questionnaires.
Time frame: Baseline and every 24 weeks, for up to 48-96 weeks
Quality-of-life
Multiple QOL tools will be used to capture physical, mental, and social well-being of the patient as well as to examine the impact of the patient's disease on the parent/guardian and family.
Time frame: Baseline and every 24 weeks, for up to 48-96 weeks
Biochemical, Molecular, Cellular and Genetic Markers of Disease Burden
Blood, urine, and CSF samples will be used to evaluate biochemical, molecular cellular, and genetic/genomic aspects of MPS IIIB.
Time frame: Baseline and every 24 weeks, for up to 48-96 weeks
Ran from Nov 2015 to primary completion in Apr 2019, 41 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Allievex Corporation